This company has been marked as potentially delisted and may not be actively trading. GX Acquisition (GXGX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock GXGX vs. AVTE, NLTX, BIOA, VIRI, WHWK, SPRB, LITS, ELYM, AADI, and ATNMShould you be buying GX Acquisition stock or one of its competitors? The main competitors of GX Acquisition include Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), BioAge Labs (BIOA), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), Spruce Biosciences (SPRB), Lite Strategy (LITS), Eliem Therapeutics (ELYM), Aadi Bioscience (AADI), and Actinium Pharmaceuticals (ATNM). GX Acquisition vs. Its Competitors Aerovate Therapeutics Neoleukin Therapeutics BioAge Labs Virios Therapeutics Whitehawk Therapeutics Spruce Biosciences Lite Strategy Eliem Therapeutics Aadi Bioscience Actinium Pharmaceuticals GX Acquisition (NASDAQ:GXGX) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends. Is GXGX or AVTE more profitable? Aerovate Therapeutics' return on equity of -90.19% beat GX Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets GX AcquisitionN/A -985.20% -6.02% Aerovate Therapeutics N/A -90.19%-77.47% Does the media favor GXGX or AVTE? In the previous week, Aerovate Therapeutics had 1 more articles in the media than GX Acquisition. MarketBeat recorded 1 mentions for Aerovate Therapeutics and 0 mentions for GX Acquisition. GX Acquisition's average media sentiment score of 0.00 equaled Aerovate Therapeutics'average media sentiment score. Company Overall Sentiment GX Acquisition Neutral Aerovate Therapeutics Neutral Which has higher valuation & earnings, GXGX or AVTE? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGX AcquisitionN/AN/A-$49.26MN/AN/AAerovate TherapeuticsN/AN/A-$75.52M-$1.70-5.38 Which has more risk & volatility, GXGX or AVTE? GX Acquisition has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Do institutionals & insiders believe in GXGX or AVTE? 61.7% of GX Acquisition shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryAerovate Therapeutics beats GX Acquisition on 4 of the 7 factors compared between the two stocks. Get GX Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for GXGX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GXGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GXGX vs. The Competition Export to ExcelMetricGX AcquisitionPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$77.98M$1.06B$6.11B$10.45BDividend YieldN/A4.84%5.73%4.77%P/E RatioN/A1.2585.3627.36Price / SalesN/A31.47596.99137.58Price / CashN/A17.6437.4661.86Price / Book15.507.6612.286.81Net Income-$49.26M-$7.71M$3.32B$276.80M GX Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GXGXGX AcquisitionN/A$2.17-4.4%N/A-19.5%$77.98MN/A0.00N/AAVTEAerovate TherapeuticsN/A$9.08+0.4%N/A-87.6%$263.18MN/A-3.0420News CoverageHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$23.47+1.6%N/A-33.6%$220.57MN/A-7.5590High Trading VolumeBIOABioAge Labs0.1284 of 5 stars$5.45-3.9%N/AN/A$195.38MN/A0.00N/AVIRIVirios TherapeuticsN/A$6.38-5.6%N/A+70.5%$122.87MN/A-23.635News CoverageWHWKWhitehawk Therapeutics1.0337 of 5 stars$2.17+1.9%N/AN/A$102.27M$21.60M-36.1721Positive NewsSPRBSpruce Biosciences0.7338 of 5 stars$175.31+9.5%$131.25-25.1%+353.9%$98.17M$4.91M-2.0320News CoverageAnalyst ForecastGap DownHigh Trading VolumeLITSLite StrategyN/A$2.54+1.6%N/AN/A$90.56MN/A-0.53100Gap DownELYMEliem TherapeuticsN/A$1.80+9.1%N/A-65.4%$53.55MN/A-3.409Gap DownAADIAadi BioscienceN/A$2.13-4.1%N/A-7.5%$52.61M$25.07M-0.9340ATNMActinium Pharmaceuticals2.1748 of 5 stars$1.50-2.6%$4.50+200.0%-11.7%$46.79MN/A-1.0830 Related Companies and Tools Related Companies AVTE Competitors NLTX Competitors BIOA Competitors VIRI Competitors WHWK Competitors SPRB Competitors LITS Competitors ELYM Competitors AADI Competitors ATNM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GXGX) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GX Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GX Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
